Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3 and X 4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
1. A method for treating a RET-associated cancer, the method comprising:
(a) detecting a dysregulation of a RET gene, a RET kinase, or the expression or activity or level of any of the same in a sample from a patient; and
(b) administering to the patient a therapeutically effective amount of a compound having the Formula I or a pharmaceutically acceptable salt or solvate thereof:
wherein:
X 1 is CH or N;
X 2 is CH or N;
X 3 is CH or N;
X 4 is CH or N;
wherein one or two of X 1 , X 2 , X 3 and X 4 is N;
A is CN;
B is hetAr 1 ;
hetAr 1 is a 5-membered heteroaryl ring having 1-3 ring nitrogen atoms, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C1-C6 alkyl, hydroxyC1-C6 alkyl, fluoroC1-C6 alkyl, difluoroC1-C6 alkyl, trifluoroC1-C6 alkyl, cyanoC1-C6 alkyl, (C1-C6 alkoxy)C1-C6 alkyl, (C1-C4 alkoxy)CH 2 C(═O)—, (C1-C4 alkoxy)C(═O)C1-C3 alkyl, C3-C6 cycloalkyl, (R a R b N)C1-C6 alkyl, (R a R b N)C(═O)C1-C6 alkyl, (C1-C6 alkylSO 2 )C1-C6 alkyl, and 4-methoxybenzyl;
R a and R b are independently H or C1-C6 alkyl;
D is hetCyc 1 ;
hetCyc 1 is a 4-6 membered heterocyclic ring having 1-2 ring nitrogen atoms, wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of C1-C3 alkyl, fluoroC1-C3 alkyl, difluoroC1-C3 alkyl, trifluoroC1-C3 alkyl and OH, or said heterocyclic ring is substituted with a C3-C6 cycloalkylidene ring, or said heterocyclic ring is substituted with an oxo group;
E is
(w) Ar 2 C(═O)—,
(x) Ar 2 C1-C6 alkyl-,
(z) Ar 2 (C1-C3 alkyl)C(═O)— wherein said alkyl portion is optionally substituted with one or two groups independently selected from the group consisting of OH, C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyC1-C6 alkyl, C1-C6 alkoxy and R e R f N—, where R e and R f are independently H or C1-C6 alkyl, or R e and R f together with the nitrogen to which they are attached form a 5-6 membered azacyclic ring optionally having an additional ring heteroatom selected from N and O,
(cc) hetAr 2 (C1-C3 alkyl)C(═O)—, wherein said alkyl portion is optionally substituted with one or two groups independently selected from the group consisting of OH, C1-C6 alkyl, hydroxyC1-C6 alkyl, C1-C6 alkoxy and R e R f N—, wherein R e and R f are independently H or C1-C6 alkyl or R e and R f together with the nitrogen to which they are attached form a 5-6 membered azacyclic ring optionally having an additional ring heteroatom selected from N and O,
(dd) R 1 R 2 NC(═O)—, or
(oo) hetAr 2 C1-C6 alkyl-;
Ar 2 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy (optionally substituted with 1-3 fluoros), fluoroC1-C6 alkyl, difluoroC1-C6 alkyl, trifluoroC1-C6 alkyl, CN, a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, and R i R j N— wherein R i and R j are independently H or C1-C6 alkyl;
hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy (optionally substituted with 1-3 fluoros), fluoroC1-C6 alkyl, difluoroC1-C6 alkyl, trifluoroC1-C6 alkyl, hydroxyC1-C6 alkyl, (C3-C6)cycloalkyl, (C1-C6 alkoxy)C1-C6 alkyl, CN, OH, and R′R″N—, wherein R′ and R″ are independently H or C1-C3 alkyl;
R 1 is H, C1-C6 alkyl or (C1-C6 alkoxy)C1-C6 alkyl; and
R 2 is H, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyC1-C6 alkyl (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)C(═O), hydroxyC1-C6 alkoxy or (3-6C cycloalkyl)CH 2 O.
2. The method of claim 1 , wherein ring D is
wherein the wavy line indicates the point of attachment of Ring D to the ring comprising X 1 , X 2 , X 3 , and X 4 , and the asterisk indicates the point of attachment of Ring D to the E group.
3. The method of claim 2 , wherein ring D is
wherein the wavy line indicates the point of attachment of Ring D to the ring comprising X1, X2, X3, and X4, and the asterisk indicates the point of attachment of Ring D to the E group.
4. The method of claim 3 , wherein E is
(w) Ar 2 C(═O)—,
(x) Ar 2 C1-C6 alkyl,
(cc) hetAr 2 (C1-C3 alkyl)C(═O)— wherein the alkyl portion is optionally substituted with one or two groups independently selected from the group consisting of OH, C1-C6 alkyl, hydroxyC1-C6 alkyl, C1-C6 alkoxy and R e R f N—, wherein R e and R f are independently H or C1-C6 alkyl,
(dd) R 1 R 2 NC(═O)—, or
(oo) hetAr 2 C1-C6 alkyl.
5. The method of claim 2 , wherein Ring D is
wherein the wavy line indicates the point of attachment of Ring D to the ring comprising X1, X2, X3, and X4, and the asterisk indicates the point of attachment of Ring D to the E group.
6. The method of claim 5 , wherein E is
(dd) R 1 R 2 NC(═O)—.
7. The method of claim 1 , wherein X 1 is N, and X 2 , X 3 , and X 4 are CH.
8. The method of claim 1 , wherein X 1 is CH, X 2 is N, and X 3 and X 4 are CH.
9. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of:
or a pharmaceutically acceptable salt or solvate thereof.
10. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
11. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
12. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
13. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
14. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
15. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
16. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
17. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
18. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
19. The method of claim 1 , wherein the compound of Formula I is
or a pharmaceutically acceptable salt or solvate thereof.
20. The method of claim 1 , wherein the cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), breast cancer, cervical cancer, colorectal cancer, ganglioneuromatosis of the gastroenteric mucosa, gastric cancer, gastrointestinal stromal tumors, glioma, leukemia, lung cancer, lymphoma, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), multiple myeloma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, papillary renal cell carcinoma, paraganglioma, parathyroid hyperplasia, pheochromocytoma, and thyroid cancer.
21. The method of claim 20 , wherein the cancer is leukemia.
22. The method of claim 1 , wherein the dysregulation of a RET gene, a RET kinase, or the expression or activity or level of any of the same results in the translation of a RET fusion protein or a mutation of a RET kinase.
23. The method of claim 22 , wherein the RET fusion protein is selected from the group consisting of BCR-RET, CLIP1-RET, KIF5B-RET, CCDC6-RET, NCOA4-RET, TRIM33-RET, ERC1-RET, FGFR1OP-RET, RET-MBD1, RET-RAB61P2, RET-PRKAR1A, RET-TRIM24, RET-GOLGA5, HOOK3-RET, KTN1-RET, TRIM27-RET, AKAP13-RET, FKBP15-RET, SPECC1L-RET, TBL1XR1/RET, CEP55-RET, CUX1-RET, KIAA1468-RET, RFG8/RET, ACBDS-RET, PTC1ex9-RET, MYH13-RET, PIBF1-RET, KIAA1217-RET, and MPRIP-RET.
24. The method of claim 22 , wherein the mutation is one or more point mutations in a RET gene.
25. The method of claim 24 , wherein the one or more point mutation results in the translation of a RET protein comprising an amino acid substitution at an amino acid position selected from the group consisting of 32, 34, 40, 64, 67, 114, 145, 292, 321, 330, 338, 360, 393, 510, 511, 513, 515, 525, 531, 532, 533, 550, 591, 593, 600, 602, 603, 606, 609, 611, 618, 619, 620, 623, 624, 630, 631, 632, 634, 635, 636, 640, 641, 648, 649, 664, 665, 666, 686, 691, 694, 700, 706, 713, 736, 748, 750, 765, 766, 768, 769, 770, 771, 777, 778, 781, 788, 790, 791, 804, 805, 806, 810, 818, 819, 823, 826, 833, 841, 843, 844, 848, 852, 865, 866, 873, 876, 881, 883, 884, 886, 891, 897, 898, 900, 901, 904, 905, 907, 908, 911, 912, 918, 919, 921, 922, 930, 961, 972, 981, 982, 1009, 1015, 1017, 1041, 1064, and 1096.
26. The method of claim 24 , wherein the one or more point mutations results in the translation of a RET protein comprising an amino acid substitution selected from the group consisting of S32L, D34S, L40P, P64L, R67H, R114H, V145G, V292M, G321R, R330Q, T338I, R360W, F393L, A510V, E511K, C515S, C515W, R525W, C531R, G533C, G533S, G550E, V591I, G593E, R600Q, I602V, K603Q, K603E, Y606C, C609Y, C609S, C609G, C609R, C609F, C609W, C611R, C611S, C611G, C611Y, C611F, C611W, C618S, C618Y, C618R, C618G, C618F, C618W, F619F, C620S, C620W, C620R, C620G, C620L, C620Y, C620F, E623K, D624N, C630A, C630R, C630S, C630Y, C630F, D631N, D631Y, D631A, D631G, D631V, D631E, E632K, E632G, C634W, C634Y, C634S, C634R, C634F, C634G, C634L, C634A, C634T, R635G, T636P, T636M, A640G, A641S, A641T, V648I, S649L, A664D, H665Q, K666E, K666M, K666N, S686N, G691S, R694Q, M700L, V706M, V706A, E713K, G736R, G748C, A750P, S765P, P766S, P766M, E768Q, E768D, L769L, R770Q, D771N, N777S, V778I, Q781R, L790F, Y791F, V804L, V804M, V804E, E805K, Y806E, Y806F, Y806S, Y806G, Y806C, E818K, S819I, G823E, Y826M, R833C, P841L, P841P, E843D, R844W, R844Q, R844L, M848T, I852M, R873W, A876V, L881V, A883F, A883S, A883T, E884K, R886W, S891A, R897Q, D898V, E901K, S904F, S904C, K907E, K907M, R908K, G911D, R912P, R912Q, M918T, M918V, M918L, A919V, E921K, S922P, S922Y, T930M, F961L, R972G, R982C, M1009V, D1017N, V1041G, and M1064T.
27. The method of claim 1 , further comprising administering an additional therapy or therapeutic agent to the patient.
28. The method of claim 27 , wherein the additional therapy or therapeutic agent is selected from the group consisting of radiotherapy, cytotoxic chemotherapeutics, kinase targeted therapeutics, apoptosis modulators, signal transduction inhibitors, immune-targeted therapies, and angiogenesis-targeted therapies.
29. The method of claim 27 , wherein the additional therapy is a second RET inhibitor, an immunotherapy, or a combination thereof.